Clinical Trials
15 trialsNCT06578247 2026-04-30
QuANTUM-WILD
Daiichi Sankyo
Phase 3 Recruiting
NCT03793478 2026-04-01
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Daiichi Sankyo
Phase 1/2 Active not recruiting
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06824168 2025-12-04
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Daiichi Sankyo
Phase 2 Recruiting
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT03723681 2022-07-29
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT03552029 2022-05-20
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Terminated
NCT02039726 2021-02-24
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Daiichi Sankyo
Phase 3 Completed
NCT00462761 2020-05-11
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Daiichi Sankyo
Phase 1 Completed
NCT02984995 2020-02-17
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Daiichi Sankyo
Phase 2 Completed
NCT01565668 2019-12-27
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Daiichi Sankyo
Phase 2 Completed
NCT00989261 2019-12-11
ACE
Daiichi Sankyo
Phase 2 Completed
NCT01390337 2019-02-12
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT01468467 2019-02-12
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed